🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Results and Global Access

As per data released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which involves an injection and a pill. The study enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Medical professionals treating patients have voiced hope. Having a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is viewed as crucial to lessen the impact of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.